Study to Evaluate SBRT for EGFR Mutant NSCLC Patients Receiving Osimertinib (CULTRO)

Conditions:   EGF-R Positive Non-Small Cell Lung Cancer;   Non Small Cell Lung Cancer;   EGFR Exon 19 Deletion;   EGFR Exon 21 Mutation;   EGFR G719X Intervention:   Radiation: Stereotactic Body Radiation Therapy SBRT Sponsor:   Centro de Tratamiento e Investigación sobre Cáncer, Luis Carlos Sarmiento Angulo Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials